DC
ENZN

Davenport & Co’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Davenport & Co’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-14,200
Closed -$23.9K – 594
2013
Q3 		$23.9K Hold
14,200
– – ﹤0.01% 546
2013
Q2 		$28.4K Buy
+14,200
New +$41.6K ﹤0.01% 521

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Davenport & Co's ENZN Position: Q4 2013 in Review

Davenport & Co sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q4 2013, closing a stake of 14,200 shares — an estimated $23.9K sold.

Davenport & Co first reported a position in ENZN in Q2 2013 and held it in 2 quarters. The position peaked at $28.4K in Q2 2013. 79 funds tracked by Wall St. Rank hold ENZN as of Q4 2013.

  • Davenport & Co reported no remaining ENZON PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Davenport & Co sold 14,200 ENZON PHARMACEUTICALS INC shares in Q4 2013, an estimated $23.9K.
  • Davenport & Co first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 2 quarters.
  • Davenport & Co's ENZON PHARMACEUTICALS INC position peaked at $28.4K in Q2 2013.
  • 79 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q4 2013.

Based on Davenport & Co's 13F filing for Q4 2013, filed 31 Jan 2014.